Skip to main content

Advertisement

Table 2 Higher anti-CXCR3 and anti-CXCR4 antibody levels are associated with stable lung function parameters

From: Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis

Parameter Patients above cut-off (%) Patients below cut-off (%) p values Number of analyzed patients Hazard ratios
Deterioration ≥ 10% No deterioration Deterioration ≥ 10% No deterioration
Anti-CXCR3 antibodies
 FVC (%) 25.0 75.0 59.3 40.7 ≤ 0.01 59 0.32
 FEV1 (%) 23.5 76.5 71.1 28.9 ≤ 0.001 72 0.22
 DLCO-SB (%) 36.4 63.6 63.6 36.4 ≤ 0.05 55 0.47
 DLCO/VA (%) 42.4 57.6 70.4 29.6 ≤ 0.05 60 0.38
Anti-CXCR4 antibodies
 FVC (%) 22.2 77.8 70.0 30.0 ≤ 0.001 47 0.2
 FEV1 (%) 33.3 66.7 78.6 21.4 ≤ 0.001 61 0.27
 TLC (%) 33.3 66.7 64.7 35.3 ≤ 0.05 44 0.33
 DLCO-SB (%) 43.3 56.7 75.0 25.0 ≤ 0.05 46 0.46
 DLCO/VA (%) 39.4 60.6 82.4 17.6 ≤ 0.001 50 0.24
  1. Patients with antibody levels above and below cut-off, with and without deterioration in forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), total lung capacity (TLC), the diffusing capacity for carbon monoxide (DLCO) measured by a single breath (DLCO-SB), and DLCO/VA within 3 years, p values (log-rank test) as well as number of analyzed patients are shown
  2. Hazard ratios derived from the Cox proportional hazards model highlight the relationship between deterioration in lung function parameters and anti-CXCR3/anti-CXCR4 antibody levels